A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Perennial Allergic Rhinitis (PAR).

NCT01451541 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

848

Enrollment

INDUSTRY

Sponsor class

Conditions

Perennial Allergic Rhinitis
PAR

Interventions

DRUG: Ciclesonide nasal aerosol 37 mcg
DRUG: ciclesonide nasal aerosol 74 mcg
DRUG: Placebo

Sponsor

Sumitomo Pharma America, Inc.